Increasing evidence suggests that IL-17A and Th17 cells play a major role in autoimmune inflammation, but there are gaps in our understanding of IL-17RA signaling mechanisms. IL-17RA is expressed in ...
A case-time-control study found no association between the initiation of interleukin 17 (IL-17) receptor A inhibitors and major adverse cardiovascular events (MACEs). Researchers conducted a case-time ...
Hosted on MSN
Scientists discover the protein IL-17 that fights infection also acts on the brain, inducing anxiety or sociability
Immune molecules called cytokines play important roles in the body's defense against infection, helping to control inflammation and coordinating the responses of other immune cells. A growing body of ...
Scientists find the protein IL-17 that fights infection also acts on the brain, inducing anxiety or sociability. This adds to evidence that immune molecules can influence behavior during illness.
Researchers reveal a novel natural “decoy receptor” that protects against inflammatory bowel disease
In a study published in Nature Immunology on January 6, a research team led by Prof. QIAN Youcun from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences ...
The family of interleukin-17 (IL-17) includes six molecules that respond to infection, in addition to participating in various physiological and pathological processes. A new paper in Signal ...
Neurons (green) in a mouse brain have a receptor (cyan) that detects the immune molecule IL-17. Researchers at Washington University School of Medicine in St. Louis have discovered that a molecule ...
Beijing Innocare Pharma Tech Co. Ltd. and Innocare Pharma Ltd. have identified compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction, interleukin-17A/A (IL17A/A) ...
Cytokines are well-known players in the immune response, helping to control inflammation and coordinate the responses of other immune cells. However, a growing body of evidence suggests that some ...
NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results